Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Systemic sclerosis10.04.07.006; 07.11.02.008; 24.03.03.041; 23.03.02.021; 15.06.01.0190.000139%Not Available
Cardiomyopathy acute02.04.01.0080.000139%Not Available
Tumour marker increased13.22.01.0170.001332%Not Available
Cytomegalovirus enterocolitis11.05.01.012; 07.19.01.0200.000417%Not Available
Short-bowel syndrome12.02.03.024; 07.17.01.0100.000799%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000278%Not Available
Lip erosion07.05.01.0160.000533%Not Available
Dihydropyrimidine dehydrogenase deficiency14.09.02.001; 03.08.07.0010.001181%Not Available
Cytomegalovirus gastrointestinal infection11.05.01.014; 07.19.02.0160.000533%Not Available
Small intestine carcinoma16.13.13.002; 07.21.01.0160.000139%Not Available
Clostridium difficile infection11.02.02.009--Not Available
Peripheral paralysis17.01.04.0200.000533%Not Available
Rectal cancer metastatic16.13.01.007; 07.21.05.0030.000208%Not Available
Oesophageal cancer metastatic16.13.06.003; 07.21.06.0030.000208%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.001668%Not Available
Colon cancer metastatic16.13.01.012; 07.21.01.0100.001181%Not Available
Biliary sepsis11.01.18.005; 09.02.01.0050.000799%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.001865%Not Available
Troponin T increased13.04.01.0150.000533%
General physical condition abnormal13.15.01.0400.001332%Not Available
Female genital tract fistula23.07.04.015; 21.10.05.009; 20.08.01.007; 07.11.05.0040.000208%Not Available
Malignant peritoneal neoplasm16.13.04.005; 07.21.03.0050.000139%Not Available
Neutrophil count abnormal13.01.06.0180.001865%Not Available
Culture positive13.08.02.0030.000799%Not Available
Purulence11.01.08.0600.000533%Not Available
Gallbladder enlargement09.03.02.0050.000799%Not Available
Mycotic endophthalmitis11.03.05.025; 06.04.05.0290.000533%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000139%Not Available
Mucosal exfoliation08.01.06.0210.000139%Not Available
Tumour perforation16.32.03.0310.000533%Not Available
The 34th Page    First    Pre   34 35    Next   Last    Total 35 Pages